English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background   Siponimod (BAF312), a selective S1P 1 /S1P 5  agonist, reduces disability progression in secondary progressive MS. Recent observations suggest it could act via S1P 1 /S1P 5 -dependent anti-inflammatory and pro-myelination effects on CNS-resident cells.Objective   Generate preclinical evidence confirming siponimod's CNS penetration and activity.Methods   Siponimod's CNS penetration and distribution was explored in rodents and non-human primates (NHPs) using: Liquid Chromatography coupled to tandem Mass Spectrometry (LC-MS/MS), quantitative whole-body autoradiography (QWBA) using  14 C-radiolabeled siponimod or non-invasive single-photon emission CT (SPECT) with a validated  123 I-radiolabeled siponimod analog. Functional CNS activity was investigated by S1P 1  receptor quantification in brain homogenates.Results   In mice/rats, siponimod treatments achieved dose-dependent efficacy and dose-proportional increase in drug blood levels, with mean brain/blood drug-exposure ratio ( Brain/Blood DER) of 6–7. Efficacy in rat brain tissues was revealed by a dose-dependent reduction in brain S1P 1  levels. QWBA distribution analysis in rats indicated that [ 14 C]siponimod related radioactivity could readily penetrate CNS, with particularly high uptakes in white matter of cerebellum, corpus callosum, and medulla oblongata versus lower exposures in other areas such as olfactory bulb. SPECT monitoring in NHPs revealed CNS distribution with a  brain/blood DER of ∼6, as in rodents.Conclusion   Findings demonstrate siponimod's CNS penetration and distribution across species, with high translational potential to human.

Siponimod (BAF312) penetrates, distributes, and acts in the central nervous system: Preclinical insights